SARS-CoV-2, the virus responsible for COVID-19 ... In vitro experiments with human lung-derived Calu-3 cells showed clear ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Scientists reveal that reactivation of Epstein-Barr virus (EBV), driven by TGFβ-induced immune suppression, is a key driver ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...

Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA ...

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published ...

Although the bivalent COVID-19 vaccine conferred moderate protection against symptomatic disease, hybrid immunity provided the strongest protection.

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...